Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection

The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters.

Citation
Wills-Karp, M. et al. “Trefoil Factor 2 Rapidly Induces Interleukin 33 to Promote Type 2 Immunity During Allergic Asthma and Hookworm Infection.” Journal of Experimental Medicine 209.3 (2012): 607–622. Copyright © 2012 by The Rockefeller University Press

As Published
http://dx.doi.org/10.1084/jem.20110079

Publisher
Rockefeller University Press, The

Version
Final published version

Citable link
http://hdl.handle.net/1721.1/71751

Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported

Detailed Terms
http://creativecommons.org/licenses/by-nc-sa/3.0/
Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection

Marsha Wills-Karp,1 Reena Rani,1 Krista Dienger,1 Ian Lewkowich,1 James G. Fox,3 Charles Perkins,1 Lauren Lewis,1 Fred D. Finkelman,1,4,5 Dirk E. Smith,6 Paul J. Bryce,7 Evelyn A. Kurt-Jones,8 Timothy C. Wang,9 Umasundari Sivaprasad,2 Gurjit K. Hershey,2 and De’Broski R. Herbert1

1Division of Immunobiology and 2Division of Asthma Research, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229
3Division of Comparative Medicine, Massachusetts Institute of Technology, Cambridge, MA 02139
4Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH 45267
5Department of Medicine, Cincinnati Veterans Affairs Medical Center, Cincinnati, OH 45220
6Department of Inflammation Research, Amgen, Seattle, WA 98119
7Division of Allergy–Immunology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611
8Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01655
9Department of Medicine, Columbia University Medical Center, New York, NY 10032

The molecular mechanisms that drive mucosal T helper type 2 (Th2) responses against parasitic helminths and allergens remain unclear. In this study, we demonstrate in mice that TFF2 (trefoil factor 2), an epithelial cell–derived repair molecule, is needed for the control of lung injury caused by the hookworm parasite Nippostrongylus brasiliensis and for type 2 immunity after infection. TFF2 is also necessary for the rapid production of IL-33, a Th2-promoting cytokine, by lung epithelia, alveolar macrophages, and inflammatory dendritic cells in infected mice. TFF2 also increases the severity of allergic lung disease caused by house dust mite antigens or IL-13. Moreover, TFF2 messenger RNA expression is significantly increased in nasal mucosal brushings during asthma exacerbations in children. These experiments extend the biological functions of TFF2 from tissue repair to the initiation and maintenance of mucosal Th2 responses.

© 2012 Wills-Karp et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
TFF2 drives type 2 immunity | Wills-Karp et al.

The mechanisms that regulate IL-33 release and whether IL-33 functions as a cytokine or nuclear factor remain unclear (Carriere et al., 2007; Ohno et al., 2009). Although epithelial cell death by necrosis may serve as one mechanism for IL-33 release, recent evidence shows that viral infection can result in IL-33 production from alveolar macrophages (Chang et al., 2011). Furthermore, IL-33 administration to mice infected with the GI nematode *Trichuris muris* promotes worm expulsion (Humphreys et al., 2008), but the endogenous mechanisms that regulate IL-33 production during worm infection are currently unknown.

TFF2 promotes type 2 immunity in murine models.

**RESULTS**

**TFF2 expression is a central feature of asthma in humans and mice**

TFF2 expression is induced within airway epithelial cells of mice challenged with allergen or type 2 cytokines (Nikolaidis et al., 2003; Follettie et al., 2006). To determine whether increased TFF2 expression was a feature of human asthma, we obtained nasal mucosa biopsies from pediatric patients experiencing asthma exacerbations and compared their TFF2 messenger RNA (mRNA) levels to nonasthmatic control subjects. TFF2 was significantly elevated in asthma patients over controls (Fig. 1 A), which prompted us to evaluate the biological role of TFF2 in the pathogenesis of murine asthma driven by house dust mite (HDM) antigens or IL-13 administration. Exposure of TFF2−/− mice to HDM antigens caused significantly less AHR (Fig. 1 B) and reduced the numbers of eosinophils and neutrophils recruited into the bronchoalveolar lavage (BAL), as compared with HDM-sensitized WT mice (Fig. 1 C). There were no differences between naive WT and TFF2−/− mice in the numbers of eosinophil or neutrophil precursors within the BM (not depicted). This may suggest that TFF2−/− mice have the

**Figure 1.** Clinical asthma is marked by increased TFF2 expression, and TFF2−/− mice are resistant to HDM-induced murine asthma. (A) Quantification of TFF2 mRNA transcripts from nasal mucosal brushings of normal subjects (n = 9) or patients experiencing acute asthma exacerbation (n = 23). Each dot represents an individual patient. Vertical bars indicate the mean. (B) Airway pressure time index (APTI) of WT and TFF2−/− mice after immunization with 1× PBS or HDM antigen extract. Means ± SE of eight mice/group are shown. (C) Quantification of inflammatory cells recovered from the BAL fluid of WT and TFF2−/− mice after intratracheal administration of HDMs or saline. Means ± SE of four mice/group are shown. Data are representative of two to three independent experiments (*, P < 0.05; **, P < 0.01). n.d., not detected.
normal potential to produce granulocytes but show impaired allergic airway inflammation in response to HDM antigens.

We also investigated whether the TFF2 deficiency modulated the development of type 2 allergic lung disease in an IL-13–driven model of murine asthma (Wills-Karp et al., 1998). rIL-13–treated WT C57BL/6 mice developed robust AHR, goblet cell metaplasia, and eosinophilic airway inflammation; however, these responses were significantly attenuated in TFF2−/− mice (Fig. 2, A–C). Moreover, IL-13–treated TFF2−/− mice showed impaired induction of lung mRNA transcripts for the goblet cell–specific genes MUC5AC, CLCA3, and RETNLB (Fig. 2 D), as well as the alternatively activated macrophage marker RETNLA (Fig. 2 D). Collectively, these findings suggest that TFF2 deficiency protects mice against experimental asthma induced by allergen or IL-13 and that increased TFF2 expression in asthma patients is associated with disease exacerbation.

TFF2 regulates hookworm-mediated lung injury

TFF2 production can be rapidly induced, within minutes of mucosal injury (Taupin et al., 1999), as well as during allergen-induced inflammation (Taupin et al., 1999; Nikolaidis et al., 2003). We investigated whether TFF2 regulated tissue repair and/or TLR2–dependent host immunity against the parasitic helminth N. brasiliensis. In this model, migratory L3 enter the lung tissues between 0 and 2 d after infection and cause hemorrhagic tissue injury that resolves over several weeks (Herbert et al., 2009). As shown in Fig. 3, A, TFF2 mRNA levels increased over threefold within the lung at day 1 and within the jejunum at day 3 after infection of WT C57BL/6 mice with 500 N. brasiliensis L3. This expression pattern for TFF2 was consistent with the kinetics of parasite migration through the host and suggested a potential role for this molecule in each mucosal compartment.

To investigate whether TFF2 served a critical function within hookworm-infected lungs, we compared lung histology between infected WT and TFF2−/− strains. Although naive TFF2−/− lung tissue showed moderately enlarged alveolar space at baseline, infected TFF2−/− animals developed excessive lung hemorrhage at day 1 and enlarged distal airspaces from alveolar wall destruction at days 3 and 7 after infection (Fig. 3 B). In contrast, WT mice developed focal hemorrhagic lesions around migrating parasites at day 1 after inoculation, followed by a progressive closure of the damaged areas of lung tissue at days 3 and 7 after infection (Fig. 3 B). Collectively, these findings suggest that TFF2 deficiency protects mice against experimental asthma induced by allergen or IL-13 and that increased TFF2 expression in asthma patients is associated with disease exacerbation.

Figure 2. TFF2 is required for IL-13–driven allergic airway inflammation and airway hyperresponsiveness. (A) Airway pressure time index (APTI) of WT and TFF2−/− mice was measured 8 d after administration of rIL-13 (5 µg/mouse) or vehicle (1× PBS). Data represent mean ± SE of eight mice/group. (B) Quantification of PAS-positive cells within airway epithelium at day 8 after injection of rIL-13 or PBS. Data represent mean ± SE of eight mice/group. (C) Numbers of epithelia, macrophages, eosinophils, and lymphocytes in BAL fluid at day 8 after injection of rIL-13 or PBS. Data represent mean ± SE of eight mice/group. (D) Quantification of mRNA transcripts encoding RETNLB, MUC5AC, CLCA3, and RETNLA in the lung at day 8 after injection of rIL-13 or PBS. Data represent mean ± SE of four to six mice/group. Data are representative of four independent experiments [***, P < 0.001].
Thus, immunity against *N. brasiliensis* adult worms in the intestine is accompanied by increased TFF2 production. In the absence of TFF2, more worm eggs are passed into the environment and parasites reside within their hosts for longer periods of time.

TFF2 promotes an early TH2 response during *N. brasiliensis* infection

IL-4 and IL-13 are both necessary and sufficient for host protection against most GI nematodes (Finkelman et al., 2004) and most allergic lung immunopathologies (Wills-Karp et al., 1998). Given that TFF2−/− mice had significant defects in both worm clearance and allergic lung pathology, we postulated that TFF2 might promote type 2 cytokine production. Consistent with this hypothesis, TFF2−/− mice displayed defects in both the early (lung) and late (intestinal) stages of *N. brasiliensis* infection. In the early phase, TFF2−/− mice expressed fewer IL-4 and IL-13 lung mRNA transcripts than WT mice at day 3 after inoculation (Fig. 5 A). Intracellular IL-13 staining of TCR-β+CD4+ cells within the lung draining LNs (Fig. 5 B and Fig. S1) revealed that at day 3 after infection, TFF2−/− mice produced three- to fourfold less IL-13 than infected WT animals (Fig. 5 B and C), yet there were no obvious differences in T cell recruitment to the LN between these strains.
impaired in worm-infected TFF2

Given that early IL-4 and IL-13 production was significantly and alveolar macrophages produced IL-33 within lung epithelia.

IL-33 production within lung epithelia

TFF2 is required for hookworm-induced

IL-33 production within lung epithelia and alveolar macrophages

Given that early IL-4 and IL-13 production was significantly impaired in worm–infected TFF2−/− mice, the underlying mechanisms were further investigated. Although there are multiple epithelial cell–derived cytokines that can promote type 2 immunity (Ito et al., 2005; Schmitz et al., 2005; Saenz et al., 2010), we focused on IL-33 (IL-1-F11), an IL-1 family cytokine which has been reported to elicit Th2-associated inflammation after its release from damaged epithelial cells (Schmitz et al., 2005; Carriere et al., 2007; Kurowska-Stolarska et al., 2009). Strikingly, *N. brasiliensis*–infected WT mice produced highly elevated IL–33 levels within the BAL fluid at both days 1 and 3 after infection (Fig. 6 A). In contrast, TFF2−/− mice produced very low amounts of IL–33 at these time points (Fig. 6 A).

To identify the potential cellular sources of IL–33, our initial experiments focused on lung epithelia and macrophage/DC lineage cells within whole lung digests. We used mAb specific for either epithelial cell adhesion molecule (EpCAM), which is expressed broadly on epithelial cells, or CD11c, which is highly expressed on alveolar macrophages/DCs (van Rijt et al., 2005; Trzpis et al., 2007). Once isolated by magnetic bead sorting, IL–33 mRNA transcript levels were determined from 10^6 cells of each population. Surprisingly, IL–33 expression was induced in both lung epithelia (Fig. 6 B) and macrophages/DCs (Fig. 6 C) from *N. brasiliensis*–infected WT mice at days 1 and 3 after infection. However, parasitized TFF2−/− mice only slightly increased their IL–33 mRNA levels in these cell populations (Fig. 6, B and C). Similar differences in IL–33 levels between strains were detected by immunofluorescence staining (not depicted).

To specifically determine whether lung epithelia or alveolar macrophages produced IL–33 at the protein level, we evaluated these populations by flow cytometry. Our gating strategy defined lung epithelia as EpCAM^+^, CD45^−^, and MHC class II^−^, to exclude the large population of EpCAM^+^ cells that coexpressed CD45^+^ (common leukocyte antigen; Fig. 6 D). In WT mice, *N. brasiliensis* infection caused a 10-fold increase of IL–33^+^ lung epithelia at day 1 after infection but only a fourfold increase by day 3 (Fig. 6 E). In contrast, TFF2−/− lung epithelia showed moderate differences after infection that were not significant (Fig. 6, F and G). This demonstrates that TFF2 is necessary for the rapid, but transient induction of IL–33 within lung epithelium after *N. brasiliensis* infection.
Figure 5. Early defect T\textsubscript{H}2 expansion and RELM-\(\beta\) expression in TFF2\(-/-\) mice is responsible for delayed immunity against *N. brasiliensis* infection. (A) IL-4 and IL-13 mRNA transcripts in naive WT and TFF2\(-/-\) mice or 3 d after *N. brasiliensis* infection. Means ± SE of five to six mice/group are shown. (B) Representative dot plot showing IL-13–positive CD4\(^+\) lymphocytes within the LN of naive WT and TFF2\(-/-\) mice or 3 d after *N. brasiliensis* infection. Four individual mice/group were analyzed for infected samples, whereas naive LNs were pooled from two to three mice. (C) Mean percentage (±SE) of IL-13–positive CD4\(^+\) lymphocytes from the experiment described in B. (D) Serum IL-4 abundance, as determined by in vivo cytokine capture assay at 0, 7, and 12 d after infection. Means ± SE of five to six mice/group are shown. (E) Intestinal RELM-\(\beta\) mRNA transcript levels at 0, 7, and 12 d after infection. Means ± SE of five to six mice/group are shown. (F) *N. brasiliensis* intestinal worms recovered from intestinal lumen on day 8 from WT versus TFF2\(-/-\) mice that were injected with vehicle or rIL-4/anti–IL-4 complexes (IL-4C) at days 0 and 4. Means ± SE of five to six mice/group are shown. n.d., not detected. (G) Immunofluorescence staining for RELM-\(\beta\) within the jejunum of mice from the experiment described in F. Cell nuclei stained with DAPI. Bars, 50 \(\mu\)m. Data are representative of three to four independent experiments (*, P < 0.05; **, P < 0.01).
macrophages also up-regulated IL-33 production at both days 1 and 3 after infection. In contrast, these IL-33+ alveolar macrophages were significantly less abundant within TFF2−/− lung tissues at both time points (Fig. 6, J and K). Overall, this indicates that TFF2 promotes IL-33 mRNA and protein expression in lung epithelia and alveolar macrophages within the first 3 d after hookworm infection.

Given that TFF2 regulated IL-33 from lung epithelia, we investigated whether it was also important for IL-33 production from alveolar macrophages. Our gating strategy defined alveolar macrophages as CD11b−, CD11c+, CD317+/−, Ly6G/C−, and CD103− (Fig. 6 H; Lambrecht and Hammad, 2009). Results shown in Fig. 6 I demonstrate that WT macrophages also up-regulated IL-33 production at both days 1 and 3 after infection. In contrast, these IL-33+ alveolar macrophages were significantly less abundant within TFF2−/− lung tissues at both time points (Fig. 6, J and K). Overall, this indicates that TFF2 promotes IL-33 mRNA and protein expression in lung epithelia and alveolar macrophages within the first 3 d after hookworm infection.

TFF2 deficiency impairs IL-33 production from inflammatory DCs, and IL-33 is necessary for host immunity against N. brasiliensis

Inflammatory DCs have been shown as critical drivers for the in vivo differentiation of T(H)2 cells (Hammad et al., 2010; Phythian-Adams et al., 2010). Therefore, it was important to
determine whether TFF2 also regulated IL-33 production in this important cell population. Inflammatory DCs within mediastinal LNs (MLNs) were defined as CD11b+CD11c+MHC class II+ and FcεRI+ (Fig. 7 A; Hammad et al., 2010). Inflammatory DCs that coexpressed ST2 and IL-33 increased five-fold in percentage by day 3 after infection within WT mice, but this population was distinctly IL-33neg within TFF2−/− MLNs (Fig. 7, B and C). We did not detect these differences in naive mice (Fig. 7 B) or at day 1 after infection (not depicted).

Although ST2+IL-33+ inflammatory DCs were a relatively small population within the MLNs of *N. brasiliensis*–infected WT mice, intact ST2 signaling in the host served a critical role for the development of host immunity. Data shown in Fig. 8 indicate that treatment of WT C57BL/6 mice with two 750-µg doses of neutralizing anti-ST2 mAb significantly increased both parasite egg production (Fig. 8 A) and the numbers of adult hookworms recovered from the intestine at day 9 after infection (Fig. 8 B). Thus, TFF2 promotes IL-33 production from inflammatory DCs during the early stages of hookworm infection, and neutralization of ST2 (IL-33 receptor) impairs the normal expulsion of *N. brasiliensis* adult worms from infected hosts.

Given this novel role for TFF2 in the rapid production of IL-33 from a variety of cellular sources, we sought to determine whether the administration of rTFF2 was alone sufficient to induce a type 2 response. As eosinophils are a hallmark of type 2 inflammation and are constitutively fluorescent within IL-4 reporter mice (4Get; Voehringer et al., 2006), we inoculated naive 4Get animals i.p. with 4 µg rTFF2 over 4 d and evaluated whether these cells were recruited to the peritoneal cavity on day 5. rTFF2 administration selectively increased the percentage of eosinophils as compared with PBS treatment but did not increase the percentage of macrophages, PMNs, or lymphocytes (Fig. 9 A). rTFF2 administration did not increase the percentage of mast cells or basophils (not depicted). Importantly, ST2 was required for this effect because the increase of peritoneal eosinophils (FSCMed SScHiSiglec-F+, GFP+) was abrogated by the treatment of mice with anti-ST2 mAb during rTFF2 administration (Fig. 9 B). This is consistent with evidence that rIL-33 administration to
naive mice results in the rapid and selective recruitment of eosinophils (Schmitz et al., 2005). Collectively, these data show that increased levels of TFF2 are sufficient to rapidly induce eosinophil recruitment through a mechanism that is dependent on the IL-33 receptor ST2.

TFF2 drives antigen-specific TH2 differentiation through IL-33

Although our data indicated that TFF2 was required for IL-33 production, it remained unclear whether TFF2 could directly stimulate IL-33 release. As macrophages are known to produce more IL-33 than DCs (Ohno et al., 2009), we generated WT BM-derived macrophages (BMDMs) and treated these cells with rTFF2 and/or bacterial LPS followed by quantitation of mRNA transcripts for the canonical T_{H2}-promoting cytokines, IL-33, IL-25, and thymic stromal lymphopoietin (TSLP). Surprisingly, TFF2 itself was a selective stimulus for IL-33, whereas TFF2 alone did not induce expression of IL-25 or TSLP (Fig. 10 A). As expected, LPS alone induced a moderate increase of IL-33, but co-administration of TFF2 and LPS actually reduced IL-33 levels compared with TFF2 alone (Fig. 10 A). In contrast, co-administration of TFF2 and LPS stimulated a significant increase of IL-25, which suggested a possible synergistic mechanism regarding the production of this type 2–promoting cytokine (Fig. 10 A).

To directly test whether TFF2-induced IL-33 production alone was sufficient to drive T_{H2} cell differentiation from naive T cell precursors, rTFF2-exposed BMDMs were used to stimulate naive OVA-specific CD4+ T cells (OTII). T cell lineage commitment was determined by mRNA quantification for levels of the following transcription factors: TBET/TBX21 (TH1), GATA3 (TH2), RORC (TH17), and FOXP3 (T reg). Within 96 h of co-culture, rTFF2-treated, OVA-pulsed BMDMs increased GATA3 expression nearly 10-fold, whereas co-cultures containing naive OTII cells with mock-treated, OVA-pulsed BMDMs did not up-regulate GATA3 (Fig. 10 B). Interestingly, rTFF2 treatment moderately suppressed TBET, RORC, and FOXP3 expression compared with mock-treated, OVA-pulsed BMDMs (Fig. 10 B). Targeted knockdown of IL-33 in BMDMs blocked TFF2-driven GATA3 expression and IL-13 production but increased TBET expression and IFN-γ production (Fig. 10, C and D). Moreover, rTFF2-treatment of OVA-pulsed BM-derived DCs (BMDCs) also caused a significant up-regulation of GATA3 expression within the OVA-specific OTII cells (Fig. 10 E). Overall, these findings demonstrated that TFF2 functioned as a specific stimulus for IL-33 production, which, at least in this in vitro co-culture system, functioned to selectively drive antigen-specific T_{H2} differentiation from naive T cell precursors.

TFF2-induced IL-33 production requires CXCR4 but not ST2 or MyD88

To investigate the mechanisms required for TFF2-mediated IL-33 production, naive mice results in the rapid and selective recruitment of eosinophils (Schmitz et al., 2005). Collectively, these data show that increased levels of TFF2 are sufficient to rapidly induce eosinophil recruitment through a mechanism that is dependent on the IL-33 receptor ST2.

TFF2 drives antigen-specific TH2 differentiation through IL-33

Although our data indicated that TFF2 was required for IL-33 production, it remained unclear whether TFF2 could directly stimulate IL-33 release. As macrophages are known to produce more IL-33 than DCs (Ohno et al., 2009), we generated WT BM-derived macrophages (BMDMs) and treated these cells with rTFF2 and/or bacterial LPS followed by quantitation of mRNA transcripts for the canonical T_{H2}-promoting cytokines, IL-33, IL-25, and thymic stromal lymphopoietin (TSLP). Surprisingly, TFF2 itself was a selective stimulus for IL-33, whereas TFF2 alone did not induce expression of IL-25 or TSLP (Fig. 10 A). As expected, LPS alone induced a moderate increase of IL-33, but co-administration of TFF2 and LPS actually reduced IL-33 levels compared with TFF2 alone (Fig. 10 A). In contrast, co-administration of TFF2 and LPS stimulated a significant increase of IL-25, which suggested a possible synergistic

Figure 9. Administration of rTFF2 to naive mice induces eosinophilia through an IL-33–dependent mechanism. (A) Naive IL-4 fluorescent reporter mice (4Get) were administered four daily i.p. injections of 1 µg rTFF2 or PBS and analyzed on day 5, and the percentage of inflammatory leukocytes from peritoneal lavage fluid were determined by Giemsa staining. Means ± SE of four mice per group are shown (*, P < 0.01). (B) Flow cytometry dot plots showing the gating strategy used to identify GFP-Siglec-F+ cells within the peritoneal cavity after the same treatments as described in A, but combined with the administration of anti-ST2 mAb or isotype-matched control Ig on days 0, 2, and 4. The percentage of total cells within the gated population is shown in the top right corner of each plot. The bottom plots are gated on cells shown within the corresponding top plot gates. Data represent mean ± SE of four mice/group. Data are representative of two to three independent experiments.
with the CXCR4 antagonist AMD3100 completely blocked TFF2-mediated IL-33 mRNA expression and protein release (Fig. 10 G). Collectively, these data indicate that TFF2 functions through CXCR4, not MyD88, for the induction of IL-33 production by BMDMs.

Lastly, to determine whether BMDMs required autocrine IL-33 signaling to promote T\(_{\text{H}2}\) differentiation, we generated BMDMs from ST2\(^{-/-}\) mice. Data show that TFF2-treated, OVA-pulsed BMDMs from ST2\(^{-/-}\) mice induced significantly more GATA3 expression within OVA-specific OTII cells as compared with nontreated ST2\(^{-/-}\) BMDMs (Fig. 10 H). Thus, TFF2-mediated effects on macrophages did not require MyD88 or autocrine IL-33 signaling but were dependent on CXCR4, the putative TFF2 receptor.

we initially focused on MyD88, the critical adaptor molecule for most Toll-like receptor and IL-1 cytokine signaling pathways (Takeuchi and Akira, 2002). Contrary to expectation, TFF2-treated BMDMs from MyD88\(^{-/-}\) mice resulted in slightly greater levels of GATA3 than induced by WT BMDMs; however, this was not significant (Fig. 10 F). Next, we asked whether TFF2 induced IL-33 release from macrophages through mechanisms that required the putative TFF2 receptor CXCR4 (Dubeykovskaya et al., 2009). Treatment of WT BMDMs

![Image of figures and tables related to TFF2-mediated IL-33 expression and protein release.

Figure 10. TFF2-treated antigen-presenting cells selectively drive T\(_{\text{H}2}\) differentiation through an IL-33–dependent mechanism. (A) BMDMs from WT mice were evaluated for mRNA expression levels of IL33, IL25, and TSLP after exposure to media (MED), 100 ng/ml LPS, 40 ng/ml rhTFF2 (TFF2), or LPS and TFF2 for 48 h. Mean ± SE of triplicate wells is shown. (B) Quantification of mRNA transcripts for GATA3, TBX21, RORC, and FOXP3 in co-cultures of OTII CD4+ T cells and BMDMs that were left untreated (MED), treated with 40 ng/ml rhTFF2, pulsed with 50 µg/ml OVA, or pretreated with TFF2 and pulsed with 50 µg/ml OVA (TFF2 + OVA). Cells were analyzed at 96 h. Data show mean ± SE of triplicate wells. (C) BMDMs were transfected with siRNA specific for IL-33 (IL-33 siRNA) or scrambled control (control) 48 h before the co-culture experiment described in B. IL-13 and IFN-γ protein levels were determined by ELISA, and mRNA levels of GATA3 and TBX21 were determined by quantitative RT-PCR. Mean ± SE of triplicate wells is shown. (D) BMDMs transfected with scrambled control or IL-33 siRNA were tested for IL-33 induction 96 h after treatment with OVA and 40 ng/ml rhTFF2. Mean ± SE of triplicate wells is shown. (E) GM-CSF differentiated BMDCs from naive WT C57BL/6 mice were stimulated as in B. Error bars indicate SE. (F) IL-33 protein levels in supernatants of WT versus MyD88\(^{-/-}\) BMDMs that were subjected to the co-culture conditions described in B. The experiment was performed two times. Data show mean ± SE of triplicate wells. (G) IL33 mRNA expression and IL-33 protein levels from WT BMDMs that were exposed to 1 µg/ml AMD3100 (CXCR4 antagonist) 24 h before exposure to stimulation with 40 ng/ml TFF2 or media for 48 h. Data show mean ± SE of triplicate wells. (H) GATA3 expression levels from co-cultures of WT naive CD4+ OTII cells and TGFST2\(^{-/-}\) BMDMs that were treated with 40 ng/ml TFF2 or left untreated before pulse with OVA (endotoxin <0.2 ng/ml free) and co-cultured with OTII cells for 96 h. Data show mean ± SE from triplicate wells. Data are representative of two to four independent experiments (*, P < 0.05; **, P < 0.01; and ***, P < 0.001).
DISCUSSION

The molecular and cellular mechanisms that initiate type 2 immunity remain topics of considerable debate and controversy. Although mechanically unclear, most of the evidence suggests that epithelial cells make important contributions toward T\(\text{h}_2\) differentiation (Artis and Grencis, 2008; Paul and Zhu, 2010). Herein, we demonstrate that the epithelial-derived repair molecule TFF2 promotes the release of IL-33, an established regulator of type 2 inflammation. In mice, this mechanism is critical for allergic lung immunopathologies and the development of host immunity against hookworms. Moreover, we demonstrate that pediatric asthma is associated with an increase of mucosal TFF2 expression.

As type 2 cytokines have previously been shown to induce TFF2 expression in the mouse lung (Nikolaidis et al., 2003; Follettie et al., 2006), we investigated its functional role in both the HDM- and IL-13–induced models of allergic asthma. HDM-induced T\(\text{h}_2\) responses may result from the injurious effects of protease-containing allergens upon airway epithelia. Indeed, HDM antigens are a major cause of clinical asthma and T\(\text{h}_2\)–driven allergic inflammation in humans (Karp, 2010). Similar to HDM antigens, rIL-13 administration in WT mice normally drives mucus hypersecretion, eosinophil recruitment, and AHR (Wills-Karp et al., 1998). TFF2/−/− mice were significantly protected against most of the allergic features induced by either HDMs or IL-13. This suggests that TFF2 may function as an effector molecule of type 2 immunity during murine asthma, which may partially explain how IL-13 causes airway epithelia to promote AHR, goblet cell activation, and mucus hypersecretion (Kuperman et al., 2002). Consistent with this hypothesis, TFF2 is known to increase mucus viscosity, which is a contributing factor to airflow obstruction during asthma pathogenesis (Thim et al., 2002; Agrawal et al., 2007). In addition, we show that children experiencing acute asthma exacerbations expressed high levels of TFF2 mRNA in the nasal mucosa. Collectively, these results suggest that TFF2 release, perhaps in response to epithelial injury caused by allergens, serves an important role in the subsequent expression of type 2 cytokine–mediated immune responses in the allergic airway mucosa.

Given the central role of TFF family proteins in epithelial cell restitution after mucosal injury (Taupin and Podolsky, 2003), we examined the effects of TFF2 deficiency on hookworm-induced lung pathology. Migration of N. brasiliensis L3 through lung tissue causes extensive hemorrhage during acute infection (Marsland et al., 2008). Pulmonary repair mechanisms subsequent to the exit of L3 from the lung result in progressive structural changes that resemble chronic obstructive pulmonary disorder and emphysema, in addition to the IL-13–dependent processes that drive increased AHR (Marsland et al., 2008). Our study demonstrates that N. brasiliensis infection causes a rapid up-regulation of lung TFF2 expression (24 h), which functionally limits the extent of tissue injury caused by migratory L3, as TFF2/−/− mice show excessive hemorrhage and accelerated development of emphysematous changes. This is consistent with TFF2’s known role in accelerating tissue repair in several other systems (Farrell et al., 2002; Poulsen et al., 2005).

Although TFF2 may induce tissue repair directly, our data show that TFF2 was also a prerequisite for the initial production of type 2 cytokines in the lung, as TFF2/−/− mice had impaired IL-4 and IL-13 responses at day 3 after inoculation compared with WT mice. This initial T\(\text{h}_2\) cell expansion at day 3 after infection was STAT-6 independent (unpublished data), as previously demonstrated by others (Jankovic et al., 2000; van Panhuys et al., 2008). Although TFF2 played an essential role in the early phase of type 2 immunity against hookworms, during later stages of the response, the TFF2 deficiency did not prevent the host from eventually producing sufficient levels of IL-4 to drive RELM-β–dependent worm expulsion (Herbert et al., 2009). Furthermore, an early administration of rIL-4 to N. brasiliensis–infected TFF2/−/− mice rapidly increased RELM-β levels and facilitated more rapid worm clearance. This demonstrated that TFF2/−/− mice had impaired immunity to N. brasiliensis infection because of an early defect in type 2 cytokines and that TFF2 functioned in a redundant manner with other T\(\text{h}_2\) effector molecules during the latter stages of infection. This is not unexpected, as there are multiple redundant mechanisms that promote T\(\text{h}_2\) responses (Neill et al., 2010; Paul and Zhu, 2010). Consistent with this hypothesis, repeated immunization of TFF2/−/− mice with chicken egg OVA over 3–4 wk resulted in only a moderate reduction of eosinophilic inflammation (Nikolaidis et al., 2006). Thus, TFF2 may primarily function to rapidly respond to injurious agents and provide early instruction toward T\(\text{h}_2\) development.

The epithelial-derived cytokines IL-25, IL-33, and TSLP are demonstrated regulators of type 2 immune responses (Fallon et al., 2006; Zaph et al., 2007; Humphreys et al., 2008). Thus, we postulated that TFF2 might induce type 2 immunity through inducing the production of one or more of these molecules. Surprisingly, TFF2 promoted IL-33 release from lung epithelia and alveolar macrophages within 24 h after infection. Even more striking was that TFF2 was required for IL-33 production within inflammatory DCs recruited to the lung draining LNs by day 3 after infection. Given the recent demonstration that inflammatory DCs are central initiators of type 2 immunity during allergic responses and worm infection (Hammad et al., 2010; Phythian-Adams et al., 2010), our data provide one potential mechanism underlying this capability. Our coculture experiments demonstrated that rTFF2 was sufficient to confer T\(\text{h}_2\)-promoting abilities upon BMDMs and BMDCs. However, it remains possible that TFF2 might also induce TSLP and/or IL-25 under certain conditions, something which is supported by our demonstration that BMDMs produced IL-25 when exposed to a combination of LPS and TFF2. Collectively, our demonstration that TFF2 regulates IL-33 production from both hematopoietic and nonhematopoietic cell lineages suggests that we have uncovered an important mechanism of mucosal immunoregulation.

IL-33 is a well-established regulator of allergic lung inflammation, anaphylactic shock, and colitis (Kurowska-Stolarska et al., 2011). In this study, we found that TFF2/−/− mice had impaired IL-33 responses at day 3 after infection due to STAT-6-independent STAT-3-dependent reductions in IL-33 and TSLP production. These results are consistent with a recent report by Keane et al. (2009) that TFF2 has direct and indirect STAT-6-independent effects on IL-33 production by AHR-activated airway epithelial cells. Given the similarity between the epithelial cell responses to hookworm and IL-13–induced asthma, we hypothesize that these findings will provide future mechanistic insights into the pathogenesis of allergic asthma.

Although the role of TFF2 in allergic lung immunopathologies remains to be elucidated, our data provide support for the systemic relevance of epithelial TFF2. In mice, TFF2 is highly expressed in the lung and mediated rapid reduction of eosinophilic inflammation (Nikolaidis et al., 2000). This strongly suggests that the epithelial-derived cytokines IL-25, IL-33, and TSLP are demonstrated regulators of type 2 immune responses (Fallon et al., 2006; Zaph et al., 2007; Humphreys et al., 2008). Thus, we postulated that TFF2 might induce type 2 immunity through inducing the production of one or more of these molecules. Surprisingly, TFF2 promoted IL-33 release from lung epithelia and alveolar macrophages within 24 h after infection. Even more striking was that TFF2 was required for IL-33 production within inflammatory DCs recruited to the lung draining LNs by day 3 after infection. Given the recent demonstration that inflammatory DCs are central initiators of type 2 immunity during allergic responses and worm infection (Hammad et al., 2010; Phythian-Adams et al., 2010), our data provide one potential mechanism underlying this capability. Our coculture experiments demonstrated that rTFF2 was sufficient to confer T\(\text{h}_2\)-promoting abilities upon BMDMs and BMDCs. However, it remains possible that TFF2 might also induce TSLP and/or IL-25 under certain conditions, something which is supported by our demonstration that BMDMs produced IL-25 when exposed to a combination of LPS and TFF2. Collectively, our demonstration that TFF2 regulates IL-33 production from both hematopoietic and nonhematopoietic cell lineages suggests that we have uncovered an important mechanism of mucosal immunoregulation.

IL-33 is a well-established regulator of allergic lung inflammation, anaphylactic shock, and colitis (Kurowska-Stolarska et al., 2011). In this study, we found that TFF2/−/− mice had impaired IL-33 responses at day 3 after infection due to STAT-6-independent STAT-3-dependent reductions in IL-33 and TSLP production. These results are consistent with a recent report by Keane et al. (2009) that TFF2 has direct and indirect STAT-6-independent effects on IL-33 production by AHR-activated airway epithelial cells. Given the similarity between the epithelial cell responses to hookworm and IL-13–induced asthma, we hypothesize that these findings will provide future mechanistic insights into the pathogenesis of allergic asthma.
cultured with OVA-specific CD4+ T cells (OTII) resulted in...

Second, TFF2 treatment of BMDMs or BMDCs co-

sinophils in 4Get mice through a mechanism that was blocked

ty

rTFF2 could rapidly induce the selective recruitment of eo-

migrate to draining LNs; (d) this results in the initial clonal

on June 18, 2012jem.rupress.org

infections: (a) TFF2 regulates IL-33 production, (b) hook-

worm infection results in IL-33 release into the lung tissue, and (c) pulmonary epithelia, alveolar macrophages, and inflammatory DCs are important sources of IL-33. Chang et al. (2011) recently demonstrated that influenza-infected rodents have IL-33+ alveolar macrophages and develop IL-13–driven AHR. These data are remarkably consistent with the central conclusions of our study, which are that infection-induced lung injury causes TFF2 release that promotes IL-33 from innate sources for the rapid development of type 2 immunity.

IL-33 has been shown to regulate the immunobiology of DCs (Rank et al., 2009), basophils (Pecaric-Petkovic et al., 2009), mast cells (Hsu et al., 2010), and T lymphocytes (Guo et al., 2009) and promote the development of alternatively activated macrophages (Kurowska-Stolarska et al., 2009; Zais et al., 2011). We found that ST2 expression on macrophages was not essential in order for TFF2 to instruct these cells to drive antigen-specific GATA3 expression within the CD4+ T cells, which implies that ST2 expression on T cells is sufficient for T\(_{h2}\) differentiation. Indeed, ST2 was necessary for host protection against N. brasiliensis. This finding is consistent with evidence that mice deficient in IL-1RL1 (subunit of IL-33 receptor) show increased susceptibility to N. brasiliensis infection and that rIL-33 administration promotes the expulsion of the whipworm T. muris (Humphreys et al., 2008; Neill et al., 2010).

Although our data also support the notion that IL-33/ ST2 signaling promotes primary T\(_{h2}\) development (Townsend et al., 2000), there is controversy regarding whether ST2 signaling promotes T\(_{h2}\) responses (Hoshino et al., 1999). Thus, we cannot rule out the possibility that IL-33 only functions to expand naive T\(_{h2}\) precursors (Guo et al., 2009). However, our data are consistent with reports that ST2 deletion or blockade impairs type 2 responses in vivo (Löning et al., 1998; Coyle et al., 1999; Townsend et al., 2000). Thus, we propose that a TFF2/IL-33 axis exists, which serves an important function in the development of T\(_{h2}\) responses and host immunity against hookworm infection.

Several lines of evidence suggest that TFF2 preferentially drives type 2 inflammation and antigen-specific T\(_{h2}\) differentiation through its ability to induce IL-33 production. First, rTFF2 could rapidly induce the selective recruitment of eosinophils in 4Get mice through a mechanism that was blocked by inhibition of ST2, the critical subunit of the IL-33 receptor. Second, TFF2 treatment of BMDMs or BMDCs co-cultured with OVA-specific CD4+ T cells (OTII) resulted in the specific induction of GATA-3, the T\(_{h2}\) lineage–specific transcription factor (Ouyang et al., 2000; Seki et al., 2004), as well as IL-13 production in culture supernatants. These cultures also contained IL-5 but no IL-10, IFN-γ, or IL-17A (unpublished data). Lastly, IL-33 production from BMDMs was necessary to promote T cell differentiation toward a T\(_{h2}\) phenotype and for the concomitant suppression of T\(_{h1}\) development. IL-33 most likely works directly on the T cells and not through autocrine effects on BMDMs, as ST2+/– macrophages also induced GATA3 expression after TFF2 treatment.

TFF2-mediated IL-33 production required the CXCR4 receptor, which is a chemokine receptor used by T cell tropic strains of the human immunodeficiency virus (Grivel and Margolis, 1999). The natural ligand for CXCR4 is SDF-1 (stromal cell–derived factor 1; Allen et al., 2004). Consistent with evidence that the TFF2 receptor is CXCR4, we demonstrate that AMD3100 (a specific antagonist of CXCR4) blocks TFF2-induced IL-33 production. This is in concordance with evidence that the CXCR4/SDF-1 axis is required for T\(_{h2}\)-mediated allergic airway disease (Gonzalo et al., 2000) and that AMD3100 abolishes cockroach-induced murine asthma (Lukacs et al., 2002). Moreover, we have preliminary evidence that AMD3100 treatment also exacerbates N. brasiliensis–induced lung injury (unpublished data).

Our model predicts that TFF2 initiates a rapid, coordinated type 2 immune response in the lung after allergen exposure or worm infection–induced mucosal injury. We propose the following: (a) within hours of insult, TFF2 secretion drives epithelial cell restitution, which prevents excessive hemorrhage and also starts the tissue remodeling process; (b) within 24 h, TFF2 promotes IL-33 release from lung epithelia and alveolar macrophages, but although IL-33 production in epithelia is rapidly lost, IL-33 production in myeloid cells is sustained for several days; (c) within 3 d, TFF2 promotes IL-33 expression within ST2+ inflammatory DCs that migrate to draining LNs; (d) this results in the initial clonal burst of antigen-specific T\(_{h2}\) cells within the LN; and (e) once sufficient amounts of IL-4 and IL-13 are produced, these cytokines drive a myriad of effector functions within epithelia and macrophages (including TFF2 production) that promote worm expulsion and asthma pathogenesis (Kuperman et al., 2002; Herbert et al., 2009).

In the context of parasitic infections, the induction of type 2 immunity and tissue remodeling protects the host against organ damage and pathogen persistence. However, in the context of asthma, excess production of type 2 cytokines and tissue repair molecules is pathogenic. It is possible that the TFF2/IL-33 axis may have evolved under selective pressure from parasitic helminths for the initiation of IL-4+ and IL-13–dependent host defense mechanisms, while simultaneously mediating the repair of damaged mucosa. This is consistent with the view that allergies and asthma represent maladaptive T\(_{h2}\) responses intended for worm parasites and suggests that TFF2 may be a possible target for therapeutic intervention in a broad array of allergic and parasitic human diseases.

MATERIALS AND METHODS

Mice, parasites, and asthma. All experiments used male WT C57BL/6 or TFF2+/– mice (C57BL/6 × 129) that have been backcrossed to the C57BL/6 background for more than six generations (Farrell et al., 2002). Although pure WT C57BL/6 B6 mice were used as controls throughout the paper, all infection data were additionally confirmed with +/+ and +/- littermate controls. 4Get mice on a BALB/c background have been described previously (Mohrs et al., 2001). Worm burdens were assessed by opening...
mouse intestines longitudinally and incubating them in PBS at 37°C for 3 h in a modified Baermann apparatus in which tissues were placed in a sieve atop a 250-ml beaker. Parasites that collected at the bottom were counted. For fecal egg counts, feces were collected, weighed, and incubated in saturated NaCl solution, and eggs were counted using McMaster slides (Herbert et al., 2009). Allergic airway responses induced by HDMs or 5 µg/ml IL-13 have been described previously (Wills-Karp et al., 1998) The Institutional Animal Care and Use Committee at the Cincinnati Children’s Hospital Medical Center (CCHMC) approved all protocols and procedures.

Subjects. Nasal epithelial samples were obtained from healthy and asthmatic children at CCHMC and processed for RNA extraction and cDNA synthesis as previously described (Guajardo et al., 2005). Asthmatic children and their parents attending the hospital clinics and emergency department at the CCHMC were invited to participate in the study. Participants were included in exacerbation of asthma (asthma-E group, n = 23) or healthy nonatopic children (control group, n = 9), as previously described (Guajardo et al., 2005).

Assessment of airway responsiveness and BAL cellularity. To evaluate airway responses, mice were anesthetized, intubated, and respired at a rate of 120 breaths per minute with a constant tidal volume (0.2 ml) and paralyzed with 25 mg/kg decamethonium bromide 24 h after the final HDM or IL-13 challenge. 50 µg/kg acetycholine was injected into the inferior vena cava, and dynamic airway pressure (cm H2O × sec) was followed for 5 min. To collect BAL fluid, lungs were lavaged three times with a 1.0-ml aliquot of cold Hanks’ balanced salt solution (Invitrogen). Recovered lavage fluid (70–80%) was centrifuged (300 g for 10 min), and the cell pellet was resuspended in 1.0 ml of 10% PBS in PBS. Total cells were counted with a hemocytometer. Slides were prepared by cytocentrifugation (Cytospin 3; Shandon Instruments) and stained with Diff-Quik (Dade Behring). BAL cell differential counts were determined using morphological criteria under a light microscope (BX40; Olympus) with evaluation of ≥500 cells/slide.

Lung histopathology. To assess airway inflammation and mucus cell content in the airway wall, lungs were excised and fixed in 10% formalin, washed in methanol, dehydrated and embedded in paraffin, and cut into 5-µm sections. Sections were mounted on slides with hematoxylin and eosin and periodic acid Schiff (PAS). The left lung was removed and fixed in 10% neutral buffered formalin. Lungs were bisected and oriented cut in the airway wall, lungs were excised and fixed in 10% formalin, and sections were included assessment of the percentage of airways with PAS-positive cells of consistent airways for comparison. Two, 5-µm sections, 30 µm apart, were included in exacerbation of asthma (asthma-E group, n = 23) or healthy nonatopic children (control group, n = 9), as previously described (Guajardo et al., 2005).

To measure IL-4 and IFN-γ secretion, airway lavage was collected by the in vivo cytokine capture assay (Finkelman and Morris, 1999). Injected biotin-labeled anticytokine mAbs in this assay form complexes with the secreted cytokines they specifically bind that have a much longer in vivo half-life than free cytokines. Consequently, the complexes accumulate in vivo and can be measured by ELISA, using wells coated with mAbs that bind to an epitope on the cytokine that is not blocked by the injected mAb. Bound biotin-mAb/cytokine complexes are detected with hors eradish peroxidase–streptavidin, followed by a lumino gensic substrate. To measure IL-4 and IFN-γ secretion, mice were injected i.v. with 10 µg biotin-BV4–1D11 (anti–IL-4 mAb), and serum was collected 6 h later and analyzed with microtiter plate wells coated with BV6D–24G2 (anti–IL-4). These antibodies were purified from ascites by ion-exchange chromatography as previously described (Herbert et al., 2008).

Long-acting IL-4 (IL-4C). IL-4C treatment was prepared by mixing rmIL-4 with the rat IgG1 anti–IL-4 mAb, 11B11, at a 2:1 molar (1:5 weight) ratio. Mice were injected i.p. with IL-4C containing 5 µg IL-4 and 25 µg anti–mouse IL-4 (11B11). IL-4C slowly dissociated, releasing biologically active IL-4 for 3–5 d. Because IL-4C contains only one molecule of IgG mAb and 11B11 blocks IL-4R binding of IL-4, IL-4C does not activate complement, interact more strongly with Fc receptors than monomeric IgG of the same rat IgG2b isotype, or bind to IL-4R. IL-4C does not promote worm expulsion or cell differentiation in IL-4R−/− mice (Herbert et al., 2009).
Statistical analysis. Statistical significance was assessed by either the two-tailed Student’s t test (two groups) or analysis of variance for multiple groups with a post-hoc Tukey test to determine significance, all performed using Prism 4.0 software (GraphPad). * P < 0.05; ** P < 0.01; and *** P < 0.001.

Online supplemental material. Fig. S1 shows the gating strategy for the identification of CD4+ TCR–B+ T lymphocytes within the MLNs. Table S1 lists the primer sequences used for this study. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20110079/DC1.

We thank Christopher Karp, Marat Khodoun, and Stephane Lajoie for critical discussions.

F.D. Finkelman is supported by a merit award from the US Department of Veterans Affairs, T.C. Wang is supported by National Institutes of Health (NIH) grant 5R01DK060758, G.K. Hershey is supported by grant U19AI02315, P.J. Bryce is supported by NIH grant RO1AI076456, M. Wills-Karp is supported by NIH grants RO1 HL67736, RO1 AI1183315, and RO1 GM083204, and RO1 HL67736, RO1 AI1183315, U19A170235, and P50ES015903, IPL is supported by NIH grant R01AI076456, M. Wills-Karp is supported by NIH grants 5R01DK060758, G.K. Hershey is supported by grant U19AI70235, P.J. Bryce is supported by NIH grant RO1AI095289 and RO1GM083204. The authors have no conflicting financial interests.

Submitted: 10 January 2011
Accepted: 20 January 2012

REFERENCES

Agrawal, A., U. Mabalirajan, A. Ram, and B. Ghosh. 2007. Novel ap-
Hertbert, D.R., J.Q. Yang, S.P. Hogan, K. Groschewitz, M. Khodoun, A. Muntz, T. Orekov, C. Perkins, Q. Wang, F. Bronbacher, et al. 2009. Intestinal epithelial cell secretion of RELM-β protects against gastrointestinal worm infection. J. Exp. Med. 206:2947–2957. http://dx.doi.org/10.1084/jem.20091268

Hertbert, D.R., T. Orekov, A. Roloson, M. Ilies, C. Perkins, W. O’Brien, S. Cederbaum, D.W. Christianson, N. Zimmermann, M.E. Rothenberg, and F.D. Finkelman. 2010. Arginase I suppresses IL-12/IL-23p40–driven intestinal inflammation during acute schistosomiasis. J. Immunol. 184:6438–6446. http://dx.doi.org/10.4049/jimmunol.0902009

Hoshino, K., S. Kashawamura, K. Kuribayashi, T. Kodama, T. Tagumura, K. Nakamichi, T. Matsuyama, T. Kakeda, and S. Akira. 1999. The absence of interleukin 1 receptor-related T1/ST2 does not affect T helper cell type 2 development and its effector function. J. Exp. Med. 190:1541–1548. http://dx.doi.org/10.1084/jem.190.10.1541

Hsu, C.L., C.V. Neilsen, and P.J. Bryce. 2010. IL-33 is produced by mast cells and regulates IgE-dependent inflammation. PLoS ONE 5:e11944. http://dx.doi.org/10.1371/journal.pone.0011944

Humphreys, N.E., D. Xu, M.R. Hepworth, F.Y. Liew, and R.K. Gencs. 2008. IL-33, a potent inducer of adaptive immunity to intestinal nematodes. J. Immunol. 180:2443–2449.

Ito, T., Y.H. Wang, O. Duramad, T. Hori, G.J. Delespesse, N. Watanabe, F.X. Qin, Z. Yao, W. Cao, and Y.J. Liu. 2005. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. J. Exp. Med. 202:1213–1223. http://dx.doi.org/10.1084/jem.20051135

Jankovic, D., M.C. Kullberg, N. Zimmermann, N.E. King, A. Mishra, S.M. Pope, F.D. Finkelman, and M.E. Rothenberg. 2003. Trefoil factor-2 is an allergen-induced gene regulated by T_{h}2 cytokines and STAT6 in the lung. Am. J. Respir. Cell Mol. Biol. 29:458–464. http://dx.doi.org/10.1165/rcmb.2002-0390OC

Karp, C.L. 2010. Guilt by intimate association: what makes an allergen an allergen? J. Allergy Clin. Immunol. 125:955–960. http://dx.doi.org/10.1016/j.jaci.2010.03.002

Keary, J., K.F. Buckland, S.A. Mathie, and C.M. Lloyd. 2009. Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2–IL-33 pathway. Am. J. Respir. Crit. Care Med. 179:772–781. http://dx.doi.org/10.1164/rccm.200805-666OC

Kuperman, D.A., X. Huang, L.L. Koth, G.H. Chang, G.M. Dolganov, Z. Zhu, J.A. Elias, D. Shappard, and D.J. Erle. 2002. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 8:885–889.

Kurowska-Stolarska, M., P. Kevin, G. Murphy, R.C. Russo, B. Stolarski, C.C. Garcia, M. Komai-Koma, N. Pitman, Y. Li, W. Niedbala, et al. 2009. IL-33 amplifies the polarization of alternatively activated macrophages. Eur. J. Immunol. 39:4789–488. http://dx.doi.org/10.1002/eji.200737827

Meyers, T.S., M.R. Fedde, E.M. Gaughan, I. Langsetmo, and H.H. Erickson. 1998. Quantification of exercise-induced pulmonary haemorrhage with bronchovascular lavage. Equine Vet. J. 30:284–288. http://dx.doi.org/10.1111/j.2042-3306.1998.tb04098.x

Mohr, M., K. Shinkai, K. Mohrs, and R.M. Locksley. 2001. Analysis of type 2 immunity in vivo with a bicistronic IL-4 reporter. Immunity. 15:303–311. http://dx.doi.org/10.1016/S1074-7613(01)00186-8

Nair, M.G., K.J. Guild, and D. Arts. 2006. Novel effector molecules in type 2 inflammation: lessons drawn from helminth infection and allergy. J. Immunol. 177:1393–1399.

Neill, D.R., S.H. Wong, A. Bellosi, R.J. Flynn, M. Daly, T.K. Langford, C. Bux, C.M. Kane, P.G. Fallon, R. Pannel, et al. 2010. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 464:1367–1370. http://dx.doi.org/10.1038/nature08900

Nikolaidis, N.M., N. Zimmermann, N.E. King, A. Mishra, S.M. Pope, F.D. Finkelman, and M.E. Rothenberg. 2003. Trefoil factor-2 is an allergen-induced gene regulated by T_{h}2 cytokines and STAT6 in the lung. Am. J. Respir. Cell Mol. Biol. 29:458–464. http://dx.doi.org/10.1165/rcmb.2002-0390OC

Nikolaidis, N.M., T.C. Wang, S.P. Hogan, and M.E. Rothenberg. 2006. Allergen induced TFF2 is expressed by mucus-producing airway epithelial cells but is not a major regulator of inflammatory responses in the murine lung. Exp. Lung Res. 32:483–497. http://dx.doi.org/10.1080/01902140601059547

Oboki, K., T. Ohno, N. Kajiwara, K. Arai, H. Morita, A. Ishii, A. Nambu, T. Abe, H. Kiyonari, K. Matsumoto, et al. 2010. IL-33 is a crucial amplifier of innate rather than acquired immunity. Proc. Natl. Acad. Sci. USA. 107:18881–18886. http://dx.doi.org/10.1073/pnas.1003059107

Ohno, T., K. Oboki, N. Kajiwara, E. Morii, K. Aozasa, R.A. Flavell, K. Oesch, H. Saito, and S. Nakae. 2009. Caspase-1, caspase-8, and calpain are dispensable for IL-33 release by macrophages. J. Immunol. 183:7890–7897. http://dx.doi.org/10.4049/jimmunol.0802449

Ouyang, W., M. Löhning, Z. Gao, M. Assenmacher, S. Ranganath, A. Radbruch, and K.M. Murphy. 2000. Stat6-independent GATA-3 status is essential for bronchial asthma and alter pulmonary dendritic cell phenotype and function. J. Immunol. 164:3047–3055.

Paul, W.E., and J. Zhu. 2010. How are T_{h}2-type immune responses initiated and amplified? Nat. Rev. Immunol. 10:225–235. http://dx.doi.org/10.1038/nri2735

Paulsen, F.P., C.W. Woon, D. Varoga, A. Jansen, F. Garreis, K. Jäger, M. Amm, D.K. Podolsky, P. Steven, N.P. Barker, and S. Sel. 2008. Intestinal trefoil factor IL-17F promotes re-epithelialization of corneal wounds. J. Biol. Chem. 283:13418–13427. http://dx.doi.org/10.1074/jbc.M800177200

Pecaric-Petkovic, T., S.A. Didichenko, S. Kaempfer, N. Spiegl, and C.A. Dahinden. 2009. Human basophils and eosinophils are the direct target leukocytes of the novel IL-1 family member IL-33. Blood. 113:1526–1534. http://dx.doi.org/10.1182/blood-2008-05-157818

Phythian-Adams, A.T., P.C. Cook, R.J. Lundie, L.H. Jones, K.A. Smith, T.A. Barr, K. Hochweller, S.M. Anderton, G.J. Hämmerling, R.M. Mazzal, and A.S. MacDonald. 2010. CD11c depletion severely disrupts T_{h}2 induction and development in vivo. J. Exp. Med. 207:2089–2096. http://dx.doi.org/10.1084/jem.20100734

Podolsky, D.K. 1997. Healing the epithelium: solving the problem from two sides. J. Gastroenterol. 32:122–126. http://dx.doi.org/10.1007/BF02123309

Published February 13, 2012

JEM Vol. 209, No. 3

621
Poulten, S.S., H. Kissow, K. Hare, B. Hartmann, and L. Thim. 2005. Luminal and parental TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. *Regul. Pept.* 126:163–171. http://dx.doi.org/10.1016/j.regpep.2004.09.007

Prêfontaine, D., J. Nadigel, F. Chouatali, S. Audusseau, A. Sensali, J. Chakir, J.G. Martin, and Q. Hamid. 2010. Increased IL-33 expression by epithelial cells in bronchial asthma. *J. Allergy Clin. Immunol.* 125:752–754. http://dx.doi.org/10.1016/j.jaci.2009.12.935

Pushparaj, P.N., H.K. Tay, S.C. H’ng, N. Pitman, D. Xu, A. McKenzie, S.A. Saenz, S.A., M.C. Siracusa, J.G. Perrigoue, S.P. Spencer, J.F. Urban Jr., A.L. Rankin, A.L., J.B. Mumm, E. Murphy, S. Turner, N. Yu, T.K. McClanahan, Taupin, D., A.G. Smulian, D.R. Greaves, S.P. Hogan, and D.R. Herbert. 2011. TGF-β limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. *Eur. J. Immunol.* 41:2000–2009. http://dx.doi.org/10.1002/eji.201041135

Rank, M.A., T. Kobayashi, H. Kozaki, K.R. Bartemes, D.L. Squillace, and H. Kita. 2009. IL-33-activated dendritic cells induce an atypical T12-type response. *J. Allergy Clin. Immunol.* 123:1047–1054. http://dx.doi.org/10.1016/j.jaci.2009.02.026

Rankin, A.L., J.B. Mumm, E. Murphy, S. Turner, N. Yu, T.K. McClanahan, P.A. Bourne, R.H. Pierce, R. Kastelein, and S. Pflanz. 2010. IL-33 induces IL-13-dependent cutaneous fibrosis. *J. Immunol.* 184:1526–1535. http://dx.doi.org/10.4049/jimmunol.0903306

Saenz, S.A., M.C. Siracusa, J.G. Perrigoue, S.P. Spencer, J.F. Urban Jr., J.E. Tocker, A.L. Budeisky, M.A. Kleinschek, R.A. Kastelein, T. Kamibayashi, et al. 2010. IL25 elicits a multipotent progenitor cell population that promotes T12 cytokine responses. *Nature* 464:1362–1366. http://dx.doi.org/10.1038/nature08901

Schmitz, J., A. Owsyng, E. Oldham, Y. Song, E. Murphy, T.K. McClanahan, G. Zurawski, M. Moshefi, J. Qin, X. Li, et al. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. *Immunity* 23:479–490. http://dx.doi.org/10.1016/j.immuni.2005.09.015

Seki, N., M. Miyazaki, W. Suzuki, K. Hayashi, K. Arima, E. Mybigheur, K. Izuhara, F. Brombacker, and M. Kubo. 2004. IL-4-induced GATA-3 expression as a time-restricted instruction switch for T\(_2\) cell differentiation. *J. Immunol.* 172:6158–6166.

Takeuchi, O., and S. Akira. 2002. MyD88 as a bottle neck in Toll/IL-1 signaling. *Curr. Top. Microbiol. Immunol.* 270:155–167. http://dx.doi.org/10.1007/978-3-642-59430-4_10

Taupin, D., and D.K. Podolsky. 2003. Trefoil factors: initiators of mucosal healing. *Nat. Rev. Mol. Cell Biol.* 4:721–732. http://dx.doi.org/10.1038/nrm1203

Taupin, D., D.C. Wu, W.K. Jeon, K. Devaney, T.C. Wang, and D.K. Podolsky. 1999. The trefoil gene family are coordinately expressed immediately–early genes. EGF receptor- and MAP kinase-dependent interregulation. *J. Clin. Invest.* 103:R31–R38. http://dx.doi.org/10.1172/JCI3304

Thim, L., F. Madsen, and S.S. Poulten. 2002. Effect of trefoil factors on the viscoelastic properties of mucus gel. *Eur. J. Clin. Investig.* 32:519–527. http://dx.doi.org/10.1046/j.1365-2362.2002.01014.x

Townsend, M.J., P.G. Fallon, D.J. Matthews, H.E. Jolin, and A.N. McKenzie. 2000. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. *J. Exp. Med.* 191:1069–1076. http://dx.doi.org/10.1084/jem.191.6.1069

Traps, M., P.M. McLaughlin, L.M. de Leij, and M.C. Harmsen. 2007. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. *Am. J. Pathol.* 171:386–395. http://dx.doi.org/10.2353/apth.2007.070152

van Panhuys, N., S.C. Tang, M. Prout, M. Camberis, D. Scarlett, J. Roberts, J. Hu-Li, W.E. Paul, and G. Le Gros. 2008. In vivo studies fail to reveal a role for IL-4 or STAT6 signaling in Th2 lymphocyte differentiation. *Proc. Natl. Acad. Sci. USA.* 105:12423–12428. http://dx.doi.org/10.1073/pnas.0806372105

van Rijt, L.S., S. Jung, A. Kleinjan, N. Vos, M. Willart, C. Duez, H.C. Hoogsteden, and B.N. Lambrecht. 2005. In vivo depletion of lung CD11c+ dendritic cells during allergen challenge abrogates the characteristic features of asthma. *J. Exp. Med.* 201:981–991. http://dx.doi.org/10.1084/jem.20042311

Voehringer, D., T.A. Reese, X. Huang, K. Shinkai, and R.M. Locksley. 2006. Type 2 immunity is controlled by IL-4/IL-13 expression in hematopoietic non-eosinophil cells of the innate immune system. *J. Exp. Med.* 203:1435–1446. http://dx.doi.org/10.1084/jem.20052448

Wills-Karp, M., J. Luyimbazi, X. Xu, B. Schofield, T.Y. Neben, C.L. Karp, and D.D. Donaldson. 1998. Interleukin-13: central mediator of allergic asthma. *Science* 282:2258–2261. http://dx.doi.org/10.1126/science.282.5397.2258

Zains, M.M., M. Kurowska-Stolarska, C. Böhm, R. Gary, C. Scholtysek, B. Stolarski, J. Reilly, S. Kerr, N.L. Millar, T. Kamradt, et al. 2011. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-alpha-mediated bone loss. *J. Immunol.* 186:6097–6105. http://dx.doi.org/10.4049/jimmunol.11003487

Zaph, C., A.E. Troy, B.C. Taylor, L.D. Berman-Bookey, K.J. Guild, Y. Du, E.A. Yost, A.D. Gruber, M.J. May, F.R. Greten, et al. 2007. Epithelial-cell-intrinsic IKK-β expression regulates intestinal immune homeostasis. *Nature* 446:552–556. http://dx.doi.org/10.1038/nature0590